Stocks
Funds
Screener
Sectors
Watchlists
CMRX

CMRX - Chimerix Inc Stock Price, Fair Value and News

$8.54 
Market Closed

CMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CMRX Price Action

CMRX RSI Chart

CMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CMRX Valuation

CMRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CMRX Fundamentals

CMRX Revenue

CMRX Earnings

CMRX Profitability

CMRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240288.0K252.0K216.0K
202325.4M17.1M8.7M324.0K
20229.9M17.9M25.9M33.8M
20215.6M4.6M3.1M2.0M
202011.4M11.4M11.0M5.4M
20198.8M9.0M10.6M12.5M
20184.2M4.7M4.2M7.2M
20175.6M4.4M4.6M4.5M
201610.8M8.4M6.8M5.7M
20154.5M7.7M8.8M10.8M
20143.4M3.5M3.8M4.0M
201332.4M27.0M7.1M4.4M
201217.5M22.9M28.3M33.7M
201100012.1M
CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEchimerix.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES89